Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
NEW YORK, Oct 30- The U.S. Securities and Exchange Commission wants to make its $602 million settlement with SAC Capital Advisors hedge fund available to people who say they are victims of illicit trading by a former SAC portfolio manager, according to a lawyer representing them. District Judge Victor Marrero, who is presiding over the SEC's case, must still...
Baxter International Inc. fell$. 49 or. 7 percent, to $69.92. Bristol-Myers Squibb Co. rose $2.14 or 4.0 percent, to $56.30. Hospira fell$. 25 or. 5 percent, to $51.82.
Baxter International Inc. rose$. 09 or. 1 percent, to $70.41. Bristol-Myers Squibb Co. fell$. 04 or. 1 percent, to $54.16. Hospira fell$. 23 or. 4 percent, to $52.07.
The Food and Drug Administration said Wednesday it cleared Pfizer's Trumenba to prevent a subtype of Meningococcal disease in people ages 10 to 25. When the bacteria infect the bloodstream they cause sepsis. Last year the University of California, Santa Barbara and Princeton University both experienced separate, unrelated outbreaks of meningococcal...
Oct 29- Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday. It is the first approved U.S. vaccine that prevents invasive disease caused by the bacterium Neisseria meningitidis B, a...
Baxter International Inc. rose$. 01 or percent, to $70.33. Bristol-Myers Squibb Co. fell$. 23 or. 4 percent, to $53.97. Hospira fell$. 16 or. 3 percent, to $52.14.
NEW YORK— A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. AK Steel Holding Corp. rose 1.5 percent to $7.46 with 11,438,400 shares traded. Alcoa Inc. fell 1.3 percent to $16.39 with 14,140,800 shares traded.
Baxter International Inc. rose$. 16 or. 2 percent, to $70.48. Bristol-Myers Squibb Co. fell$. 17 or. 3 percent, to $54.03. Hospira rose$. 18 or. 3 percent, to $52.48.
Baxter International Inc. rose$. 47 or. 7 percent, to $70.32. Bristol-Myers Squibb Co. rose$. 67 or 1.3 percent, to $54.20. Hospira rose$. 57 or 1.1 percent, to $52.30.
U.S. Treasury yields continued to rise on Tuesday amid data and expectations of Fed action.
Baxter International Inc. rose$. 01 or percent, to $69.86. Bristol-Myers Squibb Co. rose $1.03 or 1.9 percent, to $54.56. Hospira rose$. 15 or. 3 percent, to $51.88.
NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. Bank of America Corp. rose 1.3 percent to $16.80 with 67,921,300 shares traded. Cliffs Natural Resources Inc. rose 22.2 percent to $11.29 with 37,589,000 shares traded.
Oct 28- U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function. The drug, edoxaban, is a once-daily anticoagulant that inhibits Factor Xa, a protein that plays a central role in...
Pfizer earnings topped analysts' expectations on Tuesday, helped by demand for its cancer drugs and medicines in emerging markets.
Baxter International Inc. fell$. 13 or. 2 percent, to $69.72. Bristol-Myers Squibb Co. rose$. 93 or 1.7 percent, to $54.46. Hospira rose$. 23 or. 4 percent, to $51.96.
CNBC's Jim Cramer and David Faber break down the quarterly results of Pfizer and DuPont.
Wall Street looked set for a higher market open on Tuesday, as traders eyed earnings from DuPont, Pfizer and Facebook.
Some of the names on the move ahead of the open.
Oct 28- Pfizer Inc reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans in the wake of its recent failed efforts to buy rival British drugmaker AstraZeneca Plc. Excluding special items, Pfizer earned 57 cents per share.
WASHINGTON— Pfizer reported better-than-expected third quarter earnings Tuesday as higher sales in emerging markets like China helped offset missing revenue from former blockbuster drugs that have lost patent protection. Like many other drugmakers, Pfizer has lost patent exclusivity on several of its biggest blockbuster drugs that had raked in...